Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The introduction of a revolutionary drug, Lenacapavir, is poised to alter the landscape of healthcare across sub-Saharan ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

红枫湾APP： firstwordpharma.com消息，默沙东 (也译为默克）的一款长效（ 每月1次 ） 口服 HIV预防药物也宣布进入后期（III期）试验阶段，即将为HIV PrEP（暴露前预防）再添新选择。

艾滋病（AIDS，获得性免疫缺陷综合征）是一种危害极大的传染性疾病，由人类免疫缺陷病毒（HIV，也叫做艾滋病病毒）感染引起，于20世纪80年代首次被发现，一度被视为“绝症”。HIV主要有两种亚型，即HIV-1和HIV-2，相对来讲，HIV-1的复制能 ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...